- With Mayo Clinic urologist
Erik P. Castle, M.D.
read biographyclose windowBiography of
Erik P. Castle, M.D.
Erik P. Castle, M.D.
Dr. Erik Castle is a board-certified urologist who joined the Mayo Clinic staff in Arizona in 2007.
Dr. Castle is an associate professor of urology at College of Medicine, Mayo Clinic, and a senior associate consultant in the Department of Urology, where he also is assistant residency coordinator.
He was an assistant professor in the Department of Urology at Tulane University in New Orleans from 2004 to 2006 after serving as a clinical instructor/fellow at Mayo Clinic in Arizona for one year.
Dr. Castle's research interests include prostate cancer, bladder cancer and kidney cancer. He is the director of the Desert Mountain Prostate Cancer Research Fund and is the principal investigator of Castle labs housed at the Samuel C. Johnson Medical Research Building at Mayo Clinic in Arizona. His basic science research is focused on novel secondary hormonal therapies of prostate cancer as well as genomics of prostate and bladder cancers.
His surgical expertise includes laparoscopic urology, robot-assisted radical prostatectomy with nerve sparing, robot-assisted radical cystectomy with neobladder, robot-assisted retroperitoneal lymph node dissection, robot-assisted partial nephrectomy and other robotic urologic oncology procedures. He has performed many of these procedures as demonstrations internationally. He is a member of the American Association of Clinical Urologists, the American Urological Association, the Endourological Society, and the Society of Laparoendoscopic Surgeons. He is past president of the international Society of Urologic Robotic Surgery. He is also the director of the international laparoscopic nephrectomy courses throughout Mexico on behalf of the American Urologic Association.
Risk factors (2)
- Flaxseed: Does it affect risk of prostate cancer?
- Vasectomy: Does it increase my risk of prostate cancer?
Tests and diagnosis (1)
- Prostate cancer: Does PSA level affect prognosis?
Complications (1)
- Prostate cancer metastasis: Where does prostate cancer spread?
Treatments and drugs (3)
- Prostate cancer treatment: Does initial treatment preclude others later?
- Ginger for nausea: Does it work?
- Prostate cancer brachytherapy: Can I pass radiation to others?
Alternative medicine (1)
- Pomegranate juice: A cure for prostate cancer?
Prevention (1)
- Frequent sex: Does it protect against prostate cancer?
Free
E-newsletter
Subscribe to Housecall
Our weekly general interest
e-newsletter keeps you up to date
on a wide variety of health topics.
Mayo Clinic Housecall
Stay up to date on the latest health information.
What you get
- Free weekly e-newsletter
- Mayo Clinic expertise
- Recipes, tools and other helpful information
- We do not share your e-mail address
Question
Prostate cancer: Does PSA level affect prognosis?
I read that prostate cancer may grow slowly because prostate-specific antigen (PSA) keeps it in check. If so, do men with higher PSA levels have a better prognosis than men with lower PSA levels?
Answer
from Erik P. Castle, M.D.
In most cases, a higher PSA level does not mean a better prognosis, and actually the opposite is true. PSA does not keep prostate cancer "in check," but rather it is a measure of the cancer. Only in rare cases where mutated and aggressive cancers occur are low or normal PSA levels found.
PSA is a protein made by prostate tissue. Men with prostate cancer often have elevated PSA levels because the cancer cells make excessive amounts of this protein.
At the time of initial diagnosis of prostate cancer, the PSA level helps determine how likely it is that the cancer has spread (metastasized). It also helps determine how likely the cancer will be cured with treatment such as radiation or surgery. Generally, the higher your PSA level and the faster the rate at which it increases, the more prostate cancer cells you have in your body.
But this isn't always true. In some cases, the PSA level may not be elevated, despite the presence of prostate cancer. In such cases, the cancer cells often have more genetic mutations than other prostate cancer cells do, and they don't have the ability to make PSA. This type of prostate cancer is usually more aggressive and doesn't respond well to treatment. Some scientists believe that the genetic mutations in these cancer cells may allow such cancers to grow and spread more quickly.
Prostate cancer often grows very slowly. The reasons for this aren't clear. Discuss the results of your PSA test with your doctor.
Next questionProstate cancer metastasis: Where does prostate cancer spread?
- Lilja H, et al. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer. 2011;117:1210.
- Prostate-specific antigen (PSA) test. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/detection/PSA/print. Accessed Aug. 15, 2011.
- Yigitbasi O, et al. Prognostic factors in metastatic prostate cancer. Urologic Oncology. 2011;29:162.
- Meeks JJ, et al. Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml. The Journal of Urology. 2009;181:2515.
- Lilja H, et al. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nature Reviews/Cancer. 2008;8:268.
- Castle EP (expert opinion). Mayo Clinic, Scottsdale/Phoenix, Ariz. Aug. 23, 2011.
Find Mayo Clinic on